Edwards Lifesciences Corporation Stock 12‑Month Price Target Raised to $101.57, Implies 21% Upside

Edwards Lifesciences Corporation's average 12-month price target has been raised to $100.98 by 24 analysts, up from $100.03, implying a 20% upside based on the July 23 closing price. The consensus rating remains 'Buy' among 30 covering analysts, with 22 buys, 8 holds, and no sells.

According to estimates from 24 analysts, Edwards Lifesciences Corporation stock's average price target has risen from $100.03 to $100.98, with forecasts ranging from $85 to $110 per share
Based on the Jul. 23 closing price, the updated target implies approximately 20% potential upside
Consensus rating remains at “Buy” across 30 covering analysts, with 22 Buys, 8 Holds and 0 Sells

Explore more price target data and ratings for Edwards Lifesciences Corporation on the , and track all previous and future analyst recommendations for Edwards Lifesciences Corporation in the dedicated News Flow.

Disclaimer

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.